Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amarin Version 3.0 Weighs Its Options on Promising Omega-3 Pipeline

Executive Summary

Feisty Amarin is certainly undergoing a reincarnation.

You may also be interested in...



Swimming Solo For Now, Amarin Faces Challenges Commercializing Vascepa

Despite a labeling advantage when it comes to LDL, Amarin’s newly approved Vascepa faces a daunting commercial landscape, competing against Glaxo’s entrenched, soon-to-be generic Lovaza and other options for lowering triglycerides.

Pharma’s Latest Challenge: 
What To Do About New Provider-Payer Business Models

Even though their specifics are not widely known, the concepts of Medicare's accountable care organizations and other payer-provider linkups are spurring change in the pharmaceutical industry's commercial landscape.

Pharma’s Latest Challenge: 
What To Do About New Provider-Payer Business Models

Even though their specifics are not widely known, the concepts of Medicare's accountable care organizations and other payer-provider linkups are spurring change in the pharmaceutical industry's commercial landscape.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053198

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel